Novo Nordisk’s Ozempic Drug Shows Success in Kidney Trial
Wall Street Journal
Shares in Novo Nordisk topped the Stoxx Europe 600 index after it said its weight-loss drug also showed success in a trial for kidney failure in diabetes patients.
Wall Street Journal
Shares in Novo Nordisk topped the Stoxx Europe 600 index after it said its weight-loss drug also showed success in a trial for kidney failure in diabetes patients.